News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,716 Results
Type
Article (8017)
Company Profile (140)
Press Release (476558)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166771)
Career Advice (306)
Deals (25740)
Drug Delivery (7)
Drug Development (52878)
Employer Resources (14)
FDA (9761)
Job Trends (8577)
News (238249)
Policy (17931)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (488)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33165)
ALS (105)
Alzheimer's disease (976)
Antibody-drug conjugate (ADC) (264)
Approvals (10379)
Artificial intelligence (322)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (510)
Cancer (3652)
Cardiovascular disease (218)
Career advice (246)
Career pathing (1)
CAR-T (174)
Celiac Disease (1)
Cell therapy (478)
Cervical cancer (34)
Clinical research (47877)
Collaboration (1245)
Commercialization (3)
Compensation (1470)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (751)
Cystic fibrosis (85)
Data (5662)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (344)
Diagnostics (4186)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (155)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73716)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87633)
Executive appointments (702)
FDA (12399)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (919)
Gene editing (125)
Generative AI (9)
Gene therapy (318)
GLP-1 (291)
Government (951)
Grass and pollen (2)
Guidances (281)
Healthcare (9331)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (157)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (255)
Interviews (42)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (509)
Lymphoma (251)
Machine learning (27)
Management (3)
Manufacturing (534)
Marketing (8)
MASH (118)
Medical device (8657)
Medtech (8802)
Mergers & acquisitions (14385)
Metabolic disorders (709)
mRNA (55)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (39)
Neuroscience (1826)
NextGen: Class of 2026 (3153)
Non-profit (847)
Obesity (225)
Opinion (10)
Ovarian cancer (159)
Pain (172)
Pancreatic cancer (197)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (508)
Peanut (31)
People (41258)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15470)
Phase 2 (21381)
Phase 3 (14401)
Pipeline (7345)
Policy (18)
Postmarket research (1572)
Preclinical (6539)
Press Release (34)
Prostate cancer (190)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (575)
Real estate (3021)
Recruiting (6)
Regulatory (14841)
Reports (21)
Research institute (582)
Resumes & cover letters (46)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (100)
Series A (156)
Series B (121)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (323)
Venture capital (17)
Weight loss (73)
Women's health (79)
Date
Today (47)
Last 7 days (214)
Last 30 days (1582)
Last 365 days (19041)
2026 (12341)
2025 (19253)
2024 (22986)
2023 (26538)
2022 (34586)
2021 (37180)
2020 (33475)
2019 (23276)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24268)
2014 (21683)
2013 (18138)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17896)
Australia (2098)
California (11989)
Canada (3149)
China (524)
Colorado (485)
Connecticut (409)
Delaware (208)
Europe (24636)
Florida (1789)
Georgia (380)
Hawaii (3)
Idaho (46)
Illinois (703)
India (51)
Indiana (314)
Iowa (15)
Japan (403)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1202)
Massachusetts (7861)
Michigan (308)
Minnesota (560)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2621)
New Mexico (12)
New York (2822)
North Carolina (1280)
North Dakota (4)
Northern California (6003)
Ohio (278)
Oklahoma (14)
Oregon (18)
Pennsylvania (2253)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4983)
Tennessee (120)
Texas (1942)
United States (38908)
Utah (360)
Vermont (1)
Virginia (154)
Washington D.C. (38)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
484,716 Results for "veradigm inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer
November 3, 2025
·
2 min read
Business
Veradigm Provides Update on its Financial Restatement Process
Veradigm Provides Update on its Financial Restatement Process.
February 27, 2024
·
8 min read
Deals
Veradigm to Acquire ScienceIO
Veradigm to Leverage ScienceIO’s Leading Healthcare Artificial Intelligence (AI) Platform on the Company’s Large-Scale, High-Quality Data Set to Build Advanced, Private Language Models for Healthcare.
February 27, 2024
·
8 min read
BioMidwest
Veradigm to Participate in TD Cowen Annual Health Care Conference
Veradigm Inc. today announced that Dr. Yin Ho, Veradigm interim Chief Executive Officer, and Lee Westerfield, interim Chief Financial Officer, will present at the TD Cowen Annual Health Care Conference on Monday, March 4, 2024, at 9:50 AM Eastern Time.
February 28, 2024
·
1 min read
BioMidwest
Veradigm to Highlight New EHR-Integrated Care Gap Alert Solution at ViVE 2024 Conference
Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that it will be highlighting the new Veradigm Payer Insights solution at the ViVE 2024 conference in Los Angeles, CA, Feb 25-28.
February 22, 2024
·
2 min read
BioMidwest
Veradigm to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing Services
Veradigm Inc. announced today that it will now offer a conversational artificial intelligence (AI) agent for Practice Fusion Billing Services, a Veradigm Network solution.
December 11, 2023
·
2 min read
Press Releases
Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation
May 12, 2025
·
3 min read
Business
Veradigm Announces Initial Financial Guidance for Fiscal 2024
Veradigm Inc. announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Company’s Form 8-K filed on January 10, 2024, and initially reaffirmed on February 27, 2024.
March 13, 2024
·
8 min read
Deals
Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023
Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock.
January 11, 2023
·
5 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
1 of 48,472
Next
